塞来昔布在消化道肿瘤中的治疗研究进展
Progress in the Treatment of Celecoxib in Digestive Tract Tumors
DOI: 10.12677/ACM.2023.1371501, PDF,   
作者: 姜婷婷：青海大学研究生院，青海 西宁；李瑜英：青海大学附属医院，青海 西宁
关键词: 塞来昔布；食管癌；胃癌；结直肠癌；治疗研究进展；Celecoxib； Esophageal Cancer； Gastric Cancer； Colorectal Cancer； Advances in Treatment Research
摘要: 炎症细胞参与肿瘤过程，促进肿瘤细胞生长、侵袭及转移。癌症组织中不仅存在环氧合酶-2的过表达且与肿瘤的不良预后有关。塞来昔布是一种COX-2选择性抑制剂，可通过多种分子机制干预肿瘤发展并减少耐药性的形成。作用靶点广，可抑制肿瘤细胞增殖、浸润、转移及肿瘤新生血管生成、诱导肿瘤细胞分化、促进凋亡、调节肿瘤免疫、逆转肿瘤细胞多药耐药，从而发挥良好的临床抗肿瘤效果。本文试图总结阐明塞来昔布在消化道肿瘤治疗和预防中的最新研究。
Abstract: Inflammatory cells are involved in the tumor process and promote the tumor cell growth, invasion, and metastasis. Overexpression of cyclooxygenase-2 is not only present in cancer tissues but also associated with poor prognosis of tumors. Celecoxib is a selective inhibitor of COX-2 that can in tu-mor development and reduces resistance formation through a variety of molecular mechanisms. Wide targets can inhibit tumor cell proliferation, infiltration, metastasis and tumor neoangiogene-sis, induce tumor cell differentiation, promote apoptosis, regulate tumor immunity, reverse multi-drug resistance of tumor cells, so as to play a good clinical anti-tumor effect. This paper attempts to summarize the latest studies elucidating celecoxib in the treatment and prevention of digestive tract tumors.
文章引用：姜婷婷, 李瑜英. 塞来昔布在消化道肿瘤中的治疗研究进展[J]. 临床医学进展, 2023, 13(7): 10747-10752. https://doi.org/10.12677/ACM.2023.1371501

参考文献

[1] Sung, H., Ferlay, J., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Mantovani, A., Aravina, P., Xica, A. and Balkerwell, F. (2008) Can-cer-Related Inflammation. Nature, 454, 436-444. [Google Scholar] [CrossRef] [PubMed]
[3] Ritter, B. and Greten, F.R. (2019) Modulating Inflammation for Cancer Therapy. Journal of Experimental Medicine, 216, 1234-1243. [Google Scholar] [CrossRef] [PubMed]
[4] Goradel, N.H., Najafi, M., Salehi, E., Farhood, B. and Mortezaee, K. (2019) Cyclooxygenase-2 in Cancer: A Review. Journal of Cellular Physiology, 234, 5683-5699. [Google Scholar] [CrossRef] [PubMed]
[5] Zhou, H.C. and Liu, H.B. (2013) The Mechanism and Prospect of Celecoxib Treatment of Gastric Cancer. Chinese Journal of Digestive Surgery, 12, 317-320.
[6] Tołoczko-Iwaniuk, N., Dziemiańczyk-Pakieła, D., NowaszewskaB, K., Celińska-Janowicz, K. and Miltyk, W. (2019) Celecoxib in Cancer Therapy and Prevention—Review. Current Drug Targets, 20, 302-315. [Google Scholar] [CrossRef] [PubMed]
[7] 刘卫梅, 王玉, 王泽英. COX-2、MMP-14在甲状腺癌中的表达及其临床意义[J]. 实用癌症杂志, 2018, 33(6): 881-882, 886.
[8] 丰安, 周青山. 熊果酸通过下调COX-2表达降低人胃癌HGC-27细胞侵袭能力研究[J]. 胃肠病学和肝病学杂志, 2016, 25(2): 184-187.
[9] 易松, 王翠苹, 曾甫清. COX-2与MMP-14在肾癌组织中的表达水平及临床意义[J]. 现代医院, 2017, 17(1): 77-80.
[10] Jiang, W.G., Martin, T.A., Parr, C., et al. (2005) Hepatocyte Growth Factors and Their Receptors and Their Potential Value in Cancer Therapy. Critical Reviews in Oncology/Hematology, 53, 35-69. [Google Scholar] [CrossRef] [PubMed]
[11] Boccaccio, C., Sabatino, G., Mediko, E., et al. (2005) The MET Oncogene Drives a Genetic Program Linking Cancer to Hemostasis. Nature, 434, 396-400. [Google Scholar] [CrossRef] [PubMed]
[12] Sgupta, S., Cyrus, L.A., Sindrova, T., et al. (2003) Cyclooxygen-ase-2-Selective NSAIDs Inhibit Hepatocyte Growth Factor/Scattering Factor-Induced Angiogenesis. Cancer Research, 63, 8351-8359.
[13] Souza, R.F., Shewmake, K., Beer, D.G., et al. (2000) Selective Inhibition of Cyclooxygenase-2 In-hibits Cell Growth and Induces Apoptosis in Human Esophageal Adenocarcinoma Cells. Cancer Research, 60, 5767-5772. [Google Scholar] [CrossRef] 
[14] Torre, L.A., Bray, F., Siegel, R.L., et al. (2015) Global Can-cer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108. [Google Scholar] [CrossRef] [PubMed]
[15] 中国抗癌协会胃癌专业委员会. 胃癌腹膜转移防治中国专家共识[J]. 中国医学前沿杂志(电子版), 2017, 9(5): 29-40.
[16] 郎丰平, 赵毓毅, 范鹏. 甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J]. 实用癌症杂志, 2017, 32(6): 996-998.
[17] 叶永文, 刘敏, 袁华, 等. COX-2通过Notch1信号通路调控胃癌蜗牛表达[J]. 国际分子医学杂志, 2017, 40(2): 512-522.
[18] Aziz, F., Yang, X.S., Wang, X.Q. and Yan, Q. (2015) Anti-LeY Antibody Enhances the Efficacy of Celecoxib against Gastric Cancer by Downregulation of MAPKs/COX-2 Signaling Pathway: Correlation with Clinical Studies. Journal of Clinical Oncology, 141, 1221-1235. [Google Scholar] [CrossRef] [PubMed]
[19] 孟春, 卢志, 方敏, 等. 塞来昔布联合化疗药物对胃癌恶性生物学行为的影响[J]. 国际临床实验病理学杂志, 2014, 7(11): 7622-7632.
[20] 项海刚, 谢晓, 胡福强, 等. 环氧化酶-2抑制治疗胃腺癌的策略[J]. 肿瘤研究, 2014, 32(3): 1140-1148.
[21] 金国华, 徐文, 石英, 等. 塞来昔布靶向局灶粘附和白细胞经内皮迁移相关基因具有抗胃癌作用[J]. 肿瘤学报, 2016, 12(4): 2345-2350.
[22] 刘敏, 陈兆峰, 李玲玲, 等. 环氧合酶-2对人SGC-7901胃癌细胞E-cadherin的表达及迁移能力的影响[J]. 肿瘤防治研究, 2014, 41(5): 426-429.
[23] 刘铄, 陈萌, 路洪超, 等. 塞来昔布联合化疗对转移性或术后复发性晚期胃癌的疗效及药物不良反应[J]. 肿瘤药学, 2022(5): 626-631.
[24] 韩旭, 李华, 苏磊, 等. 塞来昔布联合标准化疗对胃癌患者血清血管内皮生长因子和环氧合酶-2水平的影响[J]. 生物医学代表, 2014, 2(2): 183-187.
[25] 冉俊涛, 周永宁, 唐承薇, 等. 塞来昔布术前干预对人胃癌组织E-钙粘蛋白表达的影响[J]. 癌症, 28(4): 361-365.
[26] 黄明涛, 陈志鑫, 魏斌, 等. 塞来昔布-奥曲肽联合治疗人胃腺癌术前生长抑制[J]. 药理学报, 2007, 28(11): 1842-1850.
[27] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Globalcancer Statistics 2018: GLOBOCAN Esti-mates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[28] 杨春勇, 金若天, 梁庆模. 塞来昔布通过Wnt/β-catenin信号通路对人结肠癌细胞SW480的影响[J]. 中国医药导报, 2016, 13(21): 54-57.
[29] Gurpinar, E., Grizzle, W.E. and Piazza, G.A. (2013) COX-Independent Mechanisms of Cancer Chemoprevention by Anti Inflam-Matory Drugs. Frontiers in Oncol-ogy, 3, Article 181. [Google Scholar] [CrossRef] [PubMed]
[30] Arico, S., Pattingre, S., Bauvy, C., et al. (2002) Celecoxib Induces Apoptosis by Inhibiting 3-Phosphoinositide-De- pendent Protein Kinase-1 Activity in the Human Co-lon Cancer HT-29 Cell Line. Journal of Biological Chemistry, 277, 27613-27621. [Google Scholar] [CrossRef] 
[31] Larionova, I., Kazakova, E., Grashchenko, T. and Kzhshkovska, J. (2021) New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis. Cancers (Ba-sel), 13, Article 3253.
[32] Saberi-Kalian, M., Kazgi, N., Caraglia, M., Boccherino, M., Majide, M. and Sahbukar, A. (2019) Vascular Endothelial Growth Factor: An Important Molecular Target of Curcumin. Food Science Nutrition, 59, 299-312. [Google Scholar] [CrossRef] [PubMed]
[33] Divella, R., Daniel, A., De Luca, R., Simone, M., Naleri, E., Savino, E., et al. (2017) Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Pa-tients with Colorectal Cancer. AntiCancer Research, 37, 4867-4871. [Google Scholar] [CrossRef] [PubMed]
[34] 易玲, 张文, 张华, 沈军, 邹军, 罗平, 等. 塞来昔布治疗晚期非小细胞肺癌益处的系统评价和荟萃分析[J]. 药物开发, 2018(12): 2455-2466.
[35] 赵杰, 欧斌, 韩丹, 王平, 宗毅, 朱春, 等. 肿瘤来源的CXCL5通过激活ERK/Elk-1/Snail和AKT/GSK3β/β-连环蛋白途径促进人类结直肠癌转移[J]. 摩尔癌症, 2017(16): 70.
[36] 马瑶, 李春雨. 塞来昔布抗肿瘤效应及其作用机制的研究进展[J]. 现代药学与临床, 2022, 37(5): 1144-1149.
[37] Hu, H.B., et al. (2022) Neoadjuvant PD-1 Blockade with Toripalimab, with or without Celecoxib, in Mismatch Re-pair-Deficient or Microsatellite Instability-High, Locally Advanced, Colorectal Cancer (PICC): A Single-Centre, Paral-lel-Group, Non-Comparative, Randomised, Phase 2 Trial. The Lancet Gastroenterology and Hepatology, 7, 38-48. [Google Scholar] [CrossRef] 
[38] Tran, T.Q., Hanse, E.A., Habowski, A.N., et al. (2020) α-Ketoglutarate Attenuates Wnt Signaling and Drives Differentiation in Colorectal Cancer. Nature Cancer, 1, 345-358. [Google Scholar] [CrossRef] [PubMed]
[39] Wang, Q., Zhou, Y., Rychahou, P., et al. (2018) Deptor Is a Nov-el Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth. Cancer Research, 78, 3163-3175. [Google Scholar] [CrossRef] 
[40] Dang, C.V. (2012) MYC on the Path to Cancer. Cell, 149, 22-35. [Google Scholar] [CrossRef] [PubMed]
[41] 中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020)版[J]. 中华消化外科杂志, 2020, 19(6): 563-594.

为你推荐